Hypertension, Vascular Rarefaction and Angiopoietin-1
نویسنده
چکیده
Hypertension is a very common but incompletely understood disease, especially in its pathogenesis and vascular complications occurring in the cardiovascular research filed. There are many explanations for pathological mechanisms in hypertension, including adrenergic over-reactivity, renin-angiotensin-aldosteron system abnormality and constitutionalgenetic-environmental factors. Recently emerging evidences support a novel view of hypertension, as a disease of inadequate or abnormal responses to angiogenic factors and its related vascular rarefaction and remodeling.1) To date, the best way to prevent or reduce hypertension-related vascular complications is lowering the blood pressure (BP). However, recent studies have shown that controlling BP does not completely prevent cardiovascular or renal complication in hypertension, indicating that hypertension is one of the risk factors in developing cardiovascular complications or target organ damages (TODs).2) Therefore, we need more understanding about the vascular changes related not just to BP and its control, but also to endothelial dysfunction or vascular remodeling ragarding the angiogenic factors in the pathological mechanism and TOD process in hypertension.2) The series of articles of Kim et al. showed us the various favorable vascular effects of angiopoietin-1 (Ang-1), as an angiogenic factor, on vascular rarefaction and target organ damage in hypertension. Vascular Rarefaction in Hypertension Development and Target Organ Damage
منابع مشابه
Angiopoietin-1 Gene Therapy Attenuates Hypertension and Target Organ Damage in Nitric Oxide Synthase Inhibited Spontaneously Hypertensive Rats
BACKGROUND AND OBJECTIVES In our previous study, we found that the gene transfer of a potent derivative of cartilage oligomeric matrix protein Angiopoietin-1 (COMP-Ang-1) substantially prevented hypertension, microvascular rarefaction, and target organ damage in spontaneously hypertensive rats (SHRs). The purpose of the present study was to examine the role of nitric oxide (NO) in the therapeut...
متن کاملAngiopoietin-1 prevents hypertension and target organ damage through its interaction with endothelial Tie2 receptor
AIMS The endothelium has emerged recently as a therapeutic target in the treatment of hypertension because endothelial dysfunction and subsequent vascular rarefaction cause target organ damage and further elevate blood pressure (BP). It led us to hypothesize that one of the endothelial survival factors, a potent derivative of angiopoietin-1 (cartilage oligomeric matrix protein, COMP-Ang-1), cou...
متن کاملRegulation of angiogenic factors in angiotensin II infusion model in association with tubulointerstitial injuries.
BACKGROUND Among various angiogenic factors, vascular endothelial growth factor (VEGF), angiopoietin-1 (Ang1), and angiopoietin-2 (Ang2) play crucial roles in regulating angiogenesis and vascular integrity. Infusion of angiotensin-II (ang II) induces hypertension and focal renal tubulointerstitial injuries. In the present study we investigated the renal expression of VEGF, Ang1, Ang2, and corre...
متن کاملThrombospondin-1 Induction in the Diabetic Myocardium Stabilizes the Cardiac Matrix, While Promoting Vascular Rarefaction Through Angiopoietin-2 Upregulation
متن کامل
Microvascular rarefaction and decreased angiogenesis in rats with fetal programming of hypertension associated with exposure to a low-protein diet in utero.
In hypertension, increased peripheral vascular resistance results from vascular dysfunction with or without structural changes (vessel wall remodeling and/or microvascular rarefaction). Humans with lower birth weight exhibit evidence of vascular dysfunction. The current studies were undertaken to investigate whether in utero programming of hypertension is associated with in vivo altered respons...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 41 شماره
صفحات -
تاریخ انتشار 2011